{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:43:57Z","timestamp":1788918237681,"version":"build-2803163510"},"reference-count":74,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40425-017-0271-0","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T07:41:25Z","timestamp":1502437285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma"],"prefix":"10.1136","volume":"5","author":[{"given":"Ashish M.","family":"Kamat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrinath R.","family":"Konety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Lamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Langham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Petrylak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eila C.","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,8,15]]},"reference":[{"key":"271_CR1","unstructured":"SEER Cancer Statistics Review (CSR) 1975-2014. 2017; Available from: https:\/\/seer.cancer.gov\/csr\/1975_2014\/ . [cited 2017 June 13, 2017]"},{"issue":"7637","key":"271_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"2","key":"271_CR3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11864-014-0315-3","volume":"16","author":"PL Ho","year":"2015","unstructured":"Ho PL, Williams SB, Kamat AM. Immune therapies in non-muscle invasive bladder cancer. Curr Treat Options in Oncol. 2015;16(2):5.","journal-title":"Curr Treat Options in Oncol"},{"issue":"1","key":"271_CR4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"271_CR5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","volume":"124","author":"DL Lamm","year":"1980","unstructured":"Lamm DL, et al. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol. 1980;124(1):38\u201340.","journal-title":"J Urol"},{"issue":"2 Pt 2","key":"271_CR6","first-page":"891","volume":"167","author":"A Morales","year":"1976","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;167(2 Pt 2):891\u20133. discussion 893-5","journal-title":"J Urol"},{"issue":"5","key":"271_CR7","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964\u201370.","journal-title":"J Urol"},{"issue":"3","key":"271_CR8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002400050039","volume":"26","author":"JJ Patard","year":"1998","unstructured":"Patard JJ, et al. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res. 1998;26(3):155\u20139.","journal-title":"Urol Res"},{"issue":"3","key":"271_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol. 2014;11(3):153\u201362.","journal-title":"Nat Rev Urol"},{"issue":"Suppl 7","key":"271_CR10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eursup.2008.07.009","volume":"59","author":"D Lamm","year":"2008","unstructured":"Lamm D, et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol. 2008;59(Suppl 7):651\u201366.","journal-title":"Eur Urol"},{"issue":"6","key":"271_CR11","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","volume":"186","author":"M Brausi","year":"2011","unstructured":"Brausi M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group. J Urol. 2011;186(6):2158\u201367.","journal-title":"J Urol"},{"issue":"1","key":"271_CR12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2012.08.061","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, et al. ICUD-EAU international consultation on bladder cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):36\u201344.","journal-title":"Eur Urol"},{"issue":"4","key":"271_CR13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639\u201353.","journal-title":"Eur Urol"},{"issue":"4","key":"271_CR14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","volume":"12","author":"AM Kamat","year":"2015","unstructured":"Kamat AM, et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015;12(4):225\u201335.","journal-title":"Nat Rev Urol"},{"key":"271_CR15","unstructured":"National Comprehensive Cancer Network. Bladder Cancer (Version 2.2016). October 11, 2016]; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf ."},{"issue":"4","key":"271_CR16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol. 2016;196(4):1021\u20139.","journal-title":"J Urol"},{"issue":"2","key":"271_CR17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","volume":"192","author":"AM Kamat","year":"2014","unstructured":"Kamat AM, et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol. 2014;192(2):305\u201315.","journal-title":"J Urol"},{"issue":"6","key":"271_CR18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bju.12012","volume":"112","author":"JA Witjes","year":"2013","unstructured":"Witjes JA, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS). BJU Int. 2013;112(6):742\u201350.","journal-title":"BJU Int"},{"issue":"11","key":"271_CR19","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/cncr.27973","volume":"119","author":"MD Galsky","year":"2013","unstructured":"Galsky MD, et al. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the bladder cancer advocacy network clinical trials working group. Cancer. 2013;119(11):1994\u20138.","journal-title":"Cancer"},{"issue":"5","key":"271_CR20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1200\/JCO.2011.39.5566","volume":"30","author":"R Dreicer","year":"2012","unstructured":"Dreicer R. The future of drug development in urothelial cancer. J Clin Oncol. 2012;30(5):473\u20135.","journal-title":"J Clin Oncol"},{"key":"271_CR21","unstructured":"Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, in Clinical practice guidelines we can trust, R. Graham, et al., Editors. National Academies Press (US): Washington (DC). 2011."},{"issue":"10","key":"271_CR22","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrclinonc.2013.153","volume":"10","author":"HL Kaufman","year":"2013","unstructured":"Kaufman HL, et al. The Society for Immunotherapy of Cancer Consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588\u201398.","journal-title":"Nat Rev Clin Oncol"},{"key":"271_CR23","unstructured":"Society for Immunotherapy of Cancer. Cancer Immunotherapy Guidelines. 2017; Available from: http:\/\/www.sitcancer.org\/research\/cancer-immunotherapy-guidelines . [cited 2017 February 2, 2017]."},{"issue":"16","key":"271_CR24","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016;34(16):1935\u201344.","journal-title":"J Clin Oncol"},{"issue":"4","key":"271_CR25","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol. 2000;163(4):1124\u20139.","journal-title":"J Urol"},{"issue":"3","key":"271_CR26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462\u201372.","journal-title":"Eur Urol"},{"issue":"2","key":"271_CR27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","volume":"68","author":"L Martinez-Pineiro","year":"2015","unstructured":"Martinez-Pineiro L, et al. Maintenance therapy with 3-monthly bacillus Calmette-Guerin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive Urothelial bladder carcinoma: final results of randomised CUETO study 98013. Eur Urol. 2015;68(2):256\u201362.","journal-title":"Eur Urol"},{"issue":"5","key":"271_CR28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"RJ Sylvester","year":"2010","unstructured":"Sylvester RJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57(5):766\u201373.","journal-title":"Eur Urol"},{"issue":"6","key":"271_CR29","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJ Arends","year":"2016","unstructured":"Arends TJ, et al. Results of a randomised controlled trial comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046\u201352.","journal-title":"Eur Urol"},{"issue":"6","key":"271_CR30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/00365599.2012.694906","volume":"46","author":"R Jarvinen","year":"2012","unstructured":"Jarvinen R, et al. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette-Guerin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up. Scand J Urol Nephrol. 2012;46(6):411\u20137.","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"271_CR31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2010.11.038","volume":"59","author":"W Oosterlinck","year":"2011","unstructured":"Oosterlinck W, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol. 2011;59(3):438\u201346.","journal-title":"Eur Urol"},{"issue":"6","key":"271_CR32","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.juro.2016.01.103","volume":"195","author":"C Gan","year":"2016","unstructured":"Gan C, et al. Sequential bacillus Calmette-Guerin\/electromotive drug Administration of Mitomycin C as the standard Intravesical regimen in high risk nonmuscle invasive bladder cancer: 2-year outcomes. J Urol. 2016;195(6):1697\u2013703.","journal-title":"J Urol"},{"issue":"2","key":"271_CR33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"RJ Sylvester","year":"2016","unstructured":"Sylvester RJ, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 Urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016;69(2):231\u201344.","journal-title":"Eur Urol"},{"issue":"2","key":"271_CR34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.juro.2011.10.032","volume":"187","author":"HW Herr","year":"2012","unstructured":"Herr HW. Intravesical bacillus Calmette-Guerin outcomes in patients with bladder cancer and asymptomatic bacteriuria. J Urol. 2012;187(2):435\u20137.","journal-title":"J Urol"},{"issue":"6","key":"271_CR35","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1464-410X.2012.11778.x","volume":"111","author":"HW Herr","year":"2013","unstructured":"Herr HW, Dalbagni G. Intravesical bacille Calmette-Guerin (BCG) in immunologically compromised patients with bladder cancer. BJU Int. 2013;111(6):984\u20137.","journal-title":"BJU Int"},{"issue":"3","key":"271_CR36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","volume":"176","author":"M Colombel","year":"2006","unstructured":"Colombel M, et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176(3):935\u20139.","journal-title":"J Urol"},{"issue":"5","key":"271_CR37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","volume":"104","author":"R Damiano","year":"2009","unstructured":"Damiano R, et al. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guerin-induced toxicity? BJU Int. 2009;104(5):633\u20139.","journal-title":"BJU Int"},{"issue":"2","key":"271_CR38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ucl.2013.01.012","volume":"40","author":"JB Shah","year":"2013","unstructured":"Shah JB, Kamat AM. Strategies for optimizing bacillus Calmette-Guerin. Urol Clin North Am. 2013;40(2):211\u20138.","journal-title":"Urol Clin North Am"},{"issue":"3","key":"271_CR39","doi-asserted-by":"crossref","first-page":"e2572","DOI":"10.1097\/MD.0000000000002572","volume":"95","author":"J Cui","year":"2016","unstructured":"Cui J, et al. Combination of Intravesical chemotherapy and bacillus Calmette-Guerin versus bacillus Calmette-Guerin Monotherapy in intermediate- and high-risk nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(3):e2572.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"271_CR40","first-page":"1229","volume":"20","author":"P Wu","year":"2015","unstructured":"Wu P, et al. Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: a systematic review and meta-analysis. J buon. 2015;20(5):1229\u201338.","journal-title":"J buon"},{"issue":"5","key":"271_CR41","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"KG Nepple","year":"2010","unstructured":"Nepple KG, et al. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1915\u20139.","journal-title":"J Urol"},{"issue":"1","key":"271_CR42","doi-asserted-by":"crossref","first-page":"35.e21","DOI":"10.1016\/j.urolonc.2013.02.010","volume":"32","author":"D Lamm","year":"2014","unstructured":"Lamm D, et al. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol. 2014;32(1):35.e21\u201330.","journal-title":"Urol Oncol"},{"issue":"5","key":"271_CR43","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.juro.2010.06.149","volume":"184","author":"HM Rosevear","year":"2010","unstructured":"Rosevear HM, et al. Safety and efficacy of intravesical bacillus Calmette-Guerin plus interferon alpha-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices. J Urol. 2010;184(5):1920\u20134.","journal-title":"J Urol"},{"issue":"3","key":"271_CR44","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2011.04.073","volume":"186","author":"HM Rosevear","year":"2011","unstructured":"Rosevear HM, et al. Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ. J Urol. 2011;186(3):817\u201323.","journal-title":"J Urol"},{"key":"271_CR45","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1100\/tsw.2011.30","volume":"11","author":"AJ Lightfoot","year":"2011","unstructured":"Lightfoot AJ, Rosevear HM, O'Donnell MA. Recognition and treatment of BCG failure in bladder cancer. ScientificWorldJournal. 2011;11:602\u201313.","journal-title":"ScientificWorldJournal"},{"issue":"3","key":"271_CR46","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-5347(01)66338-9","volume":"155","author":"E Solsona","year":"1996","unstructured":"Solsona E, et al. Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol. 1996;155(3):895\u20139. discussion 899-900","journal-title":"J Urol"},{"issue":"3","key":"271_CR47","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.eururo.2007.03.001","volume":"52","author":"L Mengual","year":"2007","unstructured":"Mengual L, et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. Eur Urol. 2007;52(3):752\u20139.","journal-title":"Eur Urol"},{"issue":"3","key":"271_CR48","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/bju.12516","volume":"114","author":"PH Kim","year":"2014","unstructured":"Kim PH, et al. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy. BJU Int. 2014;114(3):354\u20139.","journal-title":"BJU Int"},{"issue":"3","key":"271_CR49","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466\u20135. discussion 475-7","journal-title":"Eur Urol"},{"issue":"5","key":"271_CR50","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195\u2013203.","journal-title":"J Urol"},{"issue":"6","key":"271_CR51","doi-asserted-by":"crossref","first-page":"e96849","DOI":"10.1371\/journal.pone.0096849","volume":"9","author":"MM Vedder","year":"2014","unstructured":"Vedder MM, et al. Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours. PLoS One. 2014;9(6):e96849.","journal-title":"PLoS One"},{"issue":"2","key":"271_CR52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/bju.12495","volume":"114","author":"RJ Lammers","year":"2014","unstructured":"Lammers RJ, et al. Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy. BJU Int. 2014;114(2):193\u2013201.","journal-title":"BJU Int"},{"issue":"2","key":"271_CR53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","volume":"69","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, et al. Cytokine panel for response to Intravesical therapy (CyPRIT): Nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Guerin. Eur Urol. 2016;69(2):197\u2013200.","journal-title":"Eur Urol"},{"issue":"10","key":"271_CR54","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1158\/1055-9965.EPI-12-0982","volume":"21","author":"HP Freeman","year":"2012","unstructured":"Freeman HP. The origin, evolution, and principles of patient navigation. Cancer Epidemiol Biomark Prev. 2012;21(10):1614\u20137.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"6","key":"271_CR55","doi-asserted-by":"crossref","first-page":"dju115","DOI":"10.1093\/jnci\/dju115","volume":"106","author":"KM Freund","year":"2014","unstructured":"Freund KM, et al. Impact of patient navigation on timely cancer care: the patient navigation research program. J Natl Cancer Inst. 2014;106(6):dju115.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"271_CR56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.2013.51.7359","volume":"32","author":"EH Wagner","year":"2014","unstructured":"Wagner EH, et al. Nurse navigators in early cancer care: a randomized, controlled trial. J Clin Oncol. 2014;32(1):12\u20138.","journal-title":"J Clin Oncol"},{"issue":"23","key":"271_CR57","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","volume":"117","author":"K Chamie","year":"2011","unstructured":"Chamie K, et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011;117(23):5392\u2013401.","journal-title":"Cancer"},{"issue":"11","key":"271_CR58","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/jnci\/djq121","volume":"102","author":"JL Gore","year":"2010","unstructured":"Gore JL, et al. Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst. 2010;102(11):802\u201311.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"271_CR59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.juro.2013.07.062","volume":"191","author":"NE Mohamed","year":"2014","unstructured":"Mohamed NE, et al. Muscle invasive bladder cancer: examining survivor burden and unmet needs. J Urol. 2014;191(1):48\u201353.","journal-title":"J Urol"},{"issue":"6","key":"271_CR60","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/S0022-5347(01)66040-3","volume":"155","author":"A Bohle","year":"1996","unstructured":"Bohle A, et al. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma. J Urol. 1996;155(6):1892\u20136.","journal-title":"J Urol"},{"key":"271_CR61","doi-asserted-by":"crossref","unstructured":"Balar AV, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 20016;389(10064):67-76.","DOI":"10.1016\/S0140-6736(16)32455-2"},{"issue":"suppl 2S","key":"271_CR62","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/jco.2016.34.2_suppl.355","volume":"34","author":"JH Hoffman-Censits","year":"2016","unstructured":"Hoffman-Censits JH, et al. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). J Clin Oncol. 2016;34(suppl 2S):355.","journal-title":"J Clin Oncol"},{"issue":"10031","key":"271_CR63","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909\u201320.","journal-title":"Lancet"},{"key":"271_CR64","unstructured":"Genentech, I. Atezolizumab (Tecentriq) Highlights of Prescribing Information. 2017 4\/2017 [cited 2017 June 19th, 2017]; Available from: https:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf ."},{"issue":"11","key":"271_CR65","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol. 2016;17(11):1590\u20138.","journal-title":"Lancet Oncol"},{"issue":"3","key":"271_CR66","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312\u201322.","journal-title":"Lancet Oncol"},{"issue":"26","key":"271_CR67","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, et al. Safety and efficacy of Durvalumab (MEDI4736), an anti\u2013programmed cell death Ligand-1 immune checkpoint inhibitor, in patients with advanced Urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119\u201325.","journal-title":"J Clin Oncol"},{"key":"271_CR68","doi-asserted-by":"crossref","first-page":"44173","DOI":"10.1038\/srep44173","volume":"7","author":"J Wu","year":"2017","unstructured":"Wu J, et al. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Sci Rep. 2017;7:44173.","journal-title":"Sci Rep"},{"key":"271_CR69","doi-asserted-by":"publisher","unstructured":"Apolo AB, et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In iatients with refractory metastatic urothelial carcinoma: results from a multicenter, Phase Ib Study. J Clin Oncol, 2017;35(19):2117-24. doi: 10.1200\/JCO.2016.71.6795 .","DOI":"10.1200\/JCO.2016.71.6795"},{"issue":"2","key":"271_CR70","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-016-0191-4","volume":"4","author":"S Althammer","year":"2016","unstructured":"Althammer S, et al. 31st annual meeting and associated programs of the Society for Immunotherapy of cancer (SITC 2016): late breaking abstracts. J Immuno Ther Cancer. 2016;4(2):91.","journal-title":"J Immuno Ther Cancer"},{"key":"271_CR71","doi-asserted-by":"publisher","unstructured":"Bellmunt J, et al. KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015-26. doi: 10.1056\/NEJMoa1613683 .","DOI":"10.1056\/NEJMoa1613683"},{"key":"271_CR72","doi-asserted-by":"crossref","unstructured":"Balar, A., et al., Pembrolizumab (pembro) as first-line therapy for advanced\/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study, in ESMO 2016 Congress, October 7\u201311, Copenhagen, Denmark. 2016.","DOI":"10.1093\/annonc\/mdw435.25"},{"key":"271_CR73","unstructured":"Pembrolizumab (Keytruda) Highlights of Prescribing Information. 2017; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125514s014lbl.pdf . Accessed 19 June 2017."},{"key":"271_CR74","doi-asserted-by":"publisher","unstructured":"Balar AV, et al. Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced\/metastatic urothelial carcinoma (mUC): primary analysis of IMvigor210 cohort 1. J Clin Oncol. 2016;34(18) doi: 10.1200\/JCO.2016.34.18_suppl.LBA4500 .","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA4500"}],"updated-by":[{"DOI":"10.1186\/s40425-017-0280-z","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T00:00:00Z","timestamp":1506556800000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0271-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T01:03:36Z","timestamp":1719363816000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0271-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,15]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["271"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0271-0","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,15]]},"article-number":"68"}}